Annals of epidemiology

Using artificial intelligence to analyze patient stories about semaglutide for weight loss

Updated

Abstract

Users who took semaglutide more than 60 days reported a mean weight loss of 32.2 ± 3.1 lbs (14.6 kg).

  • Commonly reported side effects include nausea (46.9%), headache (18.4%), and vomiting (14.3%).
  • Users in the ≤ 30-day group had the highest sentiment scores (mean: 3.38).
  • Topic modeling revealed themes such as appetite suppression, medication cost, and long-term experiences.
  • Cluster analysis identified distinct user profiles, including a super-responder group with substantial weight loss.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of Competing Interest "The authors disclose that preliminary findings from this research were presented at the Annual American College of Epidemiology (ACE) Conference 2024: Integrating Epidemiology and Artificial Intelligence to Advance Public Health (September 8–11, 2024, Columbus, Ohio). The title and abstract were published as a supplement in the Annals of Epidemiology (https://doi.org/10.1016/j.annepidem.2024.07.054). Furthermore, the author is currently serving as a Board Member of the American College of Epidemiology."
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free